Crowdonomics
Shackelford Pharma Inc.

Reg A+ · Equity · Jul 2022

ClosedReg A+Equity
via the platform · last checked Aug 16, 2026
Raised
$0 / $12M max
0% of ceiling
Investors
—
—
Estimated pre-money
$68.2M
—

Financials disclosed in this offering

FY2021 · hover for source
$0
−$3.5M
FY2021
RevenueNet income
Metric
FY2021 audited
Income statement
Revenue
$0
Cost of goods sold
$0
Net income
-$3,520,134
Balance sheet
Cash
$6,118,513
Accounts receivable
$54,611
Total assets
$6,411,228
Long-term debt
$0
Total liabilities
$403,212
Other
Headcount
0

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Amendments to this offering

3 amendments
  1. Dec 9, 2022
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗
  2. Dec 8, 2022
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗
  3. Aug 25, 2022
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. Form 1-A amendments state no reason; those filed before qualification are usually responses to SEC staff review.

Deal terms

Est. pre-money$68.2M
Price / share$1.50
Shares offered8,000,000

Estimated, not stated: $1.50 × 45,463,767 securities outstanding.

Offering details

Target—
Max$12,000,000
Min investment—
OpenedJul 21, 2022
Deadline—
Days active1,542

Links & provenance

Source: SEC EDGAR
0001062993-22-016573
Last synced Aug 16, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.